Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2

Clinical Infectious Diseases

Volumn 39, Issue 2, 2004, Pages 256-263

  Beilke, Mark A ^a   Theall, Katherine P ^b   O'Brien, Megan ^b,d   Clayton, John L ^b,e   Benjamin, Stephanie M ^b,c   Winsor, Elsa L ^a   Kissinger, Patricia J ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; CELL COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEATH; DISEASE COURSE; ETHNOLOGY; FEMALE; HAZARD ASSESSMENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RACE; RESPIRATORY TRACT INFECTION; SURVIVAL; T LYMPHOCYTE; THROMBOCYTOPENIA; TIME; URINARY TRACT INFECTION; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; LOUISIANA; MALE;

EID: 3242800314     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422146     Document Type: Article

References (28)

1. Khabbaz RF, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992; 326:375-80.
2. Hershow RC, Galai N, Fukuda K, et al. An international collaborative study on the effects of co-infection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis 1996; 174:309-17.
3. Guimareaes ML, Bastos FI, Telles PR, et al. Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II. J Clin Virol 2001; 21:143-51.
4. Egan JF, O'Leary B, Lewis MJ, et al. High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. AIDS Res Hum Retroviruses 1999; 15:699-705.
5. Gotuzzo E, Escamilla J, Phillips IA, et al. The impact of human T-lymphotropic virus type I/II infection on the prognosis of sexually acquired cases of acquired immunodeficiency syndrome. Arch Inten Med 1992; 152:1429-32.
6. Soriano V, Martinez-Zapico R, Gutierrez M, Guerra A, Dronda F. Rising incidence of human T-cell leukaemia/lymphoma virus type II in Spanish drug users [letter]. AIDS 1997; 11:549-50.
7. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001; 15:1295-302.
8. Briggs, NC, Battjes RJ, Cantor KP, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. J Infect Dis 1995; 172:51-8.
9. Salemi M, Cattaneo E, Casoli C, Bertazzoni U. Identification of IIa and IIb molecular subtypes of human T-cell lymphotropic virus type II among Italian injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:516-20.
10. Askild A, Samdal HH, Heger B. Co-infection with HIV-1/HTLV-II and the risk of progression to AIDS and death. The Oslo HIV Cohort Study Group. APMIS 1996; 104:666-72.
11. Brites C, Alencar R, Gusmao R, et al. Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1-infected patients in Bahia, Brazil. AIDS 2001; 15:2053-5.
12. Figueroa JP, Ward E, Morris J, et al. Incidence of HIV and HTLV-1 infection among sexually transmitted disease clinic attenders in Jamaica. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:232-7.
13. Hishida O, Ayisi NK, Aidoo M, et al. Serological survey of HIV-1, HIV-2 and HTLV-I for suspected AIDS cases in Ghana. AIDS 1994; 8:1257-61.
14. Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak OF. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:67-71.
15. + lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:308-11.
16. Harrison LH, Quinn TC, Schechter M. Human T cell lymphotropic virus type I does not increase human immunodeficiency virus viral load in vivo. J Infect Dis 1997; 175:438-40.
17. Chavance M, Neisson-Vernant C, Quist D, Monplaisir N, Armengaud B, Chout R. HIV/HTLV-I co-infection and clinical grade at diagnosis. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:91-5.
18. Blattner W. Human T lymphotropic viruses: HTLV-I and HTLV-II. In: Broder S, Merrigan TC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams and Wilkins, 1994:887-9.
19. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen ISY. High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989; 244:471-5.
20. Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999; 159:1485-91.
21. Zehender G, Colasant C, Santambrogio S, et al. Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr 2002; 31:440-7.
22. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated oumyelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. Neurology 1997; 48:315-20.
23. Zeiger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
24. Casoli C, Turci M, Pilotti E, Ciancianaini P, Bertazzoni U. Epidemiological and molecular data on 170 HTLV-II cases of Italian IDUs [abstract 03]. AIDS Res Human Retrovirus 2003; 19(Suppl):7.
25. Murphy EL, Watanabe K, Nass CC, Ownby H, William A, Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180:1777-83.
26. Lewis MJ, Gautier VW, Wang XP, Kaplan MH, Hall WW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-1 coinfected individuals. J Immunol 2000; 165:4127-32.
27. Bovolenta C, Pilotti E, Mauri M, Panzeri B, et al. Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1. J Immunol 2002; 169:4443-9.
28. Hill SA, Lloyd PA, McDonald S, Wykoff J, Derse D. Susceptibility of human T cell leukemia virus to nucleoside reverse transcriptase inhibitors. J Infect Dis 2003; 188:424-7.